Slingshot Insights | Kykof Overview

KYKOF Overview

Upcoming Projects (KYKOF)

Don’t see a project related to the company you care about? Create your own!

Executed Projects (KYKOF)

3: Discussing the potential of rocatinlimab, an investigational therapy targeting the OX40 receptor, for adults with moderate to severe atopic dermatitis and the recently announced top-line results of the Phase 3 ROCKET HORIZON trial.
Tickers: KYKOF, AMGN
Executed On: Oct 21, 2024 at 10:00 AM EDT
2: Discussing the potential of rocatinlimab, an investigational therapy targeting the OX40 receptor, for adults with moderate to severe atopic dermatitis and the recently announced top-line results of the Phase 3 ROCKET HORIZON trial.
Tickers: KYKOF, AMGN
Executed On: Oct 15, 2024 at 09:40 AM EDT
Discussing the potential of rocatinlimab, an investigational therapy targeting the OX40 receptor, for adults with moderate to severe atopic dermatitis and the recently announced top-line results of the Phase 3 ROCKET HORIZON trial.
Tickers: KYKOF, AMGN
Executed On: Oct 10, 2024 at 01:00 PM EDT
A Third Look: Delving into the phase 2b clinical trial data on rocatinlimab (KHK4083/AMG 451) for the treatment of atopic dermatitis released at AAD 2023.
Ticker: KYKOF
Executed On: Apr 18, 2023 at 04:00 PM EDT
A Second Look: Delving into the phase 2b clinical trial data on rocatinlimab (KHK4083/AMG 451) for the treatment of atopic dermatitis released at AAD 2023.
Ticker: KYKOF
Executed On: Mar 31, 2023 at 11:00 AM EDT
Delving into the phase 2b clinical trial data on rocatinlimab (KHK4083/AMG 451) for the treatment of atopic dermatitis released at AAD 2023.
Ticker: KYKOF
Executed On: Mar 23, 2023 at 04:45 PM EDT

Upcoming & Overdue Catalysts (KYKOF)

Don’t see a catalyst related to the company you care about? Create your own!

Strategic Initiatives (KYKOF)

Don’t see a strategic initiative related to the company you care about? Create your own!